Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment CL LYMPH MYELOM LEUK
A robust and validated integrated prognostic index for defining risk groups in adult ALL: A EWALL collaborative study Blood Adv
Identification of novel NUP98 fusion partners and co-mutations in Acute Myeloid Leukemia: an adult cohort study Blood Adv
Cellular and clinical impact of protein phosphatase enzyme epigenetic silencing in multiple cancer tissues Hum Genomics
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022 EClinicalMedicine
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options Ann Hematol
DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study BRIT J HAEMATOL
Improving the EASIX' predictive power for NRM in adults undergoing allogeneic hematopoietic cell transplantation BONE MARROW TRANSPL
EASIX and cardiac adverse events after allogeneic hematopoietic cell transplantation BONE MARROW TRANSPL
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study LEUKEMIA LYMPHOMA